HMGB1 Polypeptide Engineering for Inflammation-Free Tissue Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing HMGB1 variants, such as 3S-HMGB1, induce deleterious inflammation and proinflammatory signaling, limiting their effectiveness in promoting tissue regeneration, while fully-reduced HMGB1 (FR-HMGB1) has equivalent regenerative properties but lacks specificity in signaling pathways.
Innovation Solution
A modified HMGB1 polypeptide, dBB12L, is designed to eliminate RAGE, TLR-2, and TLR-4 signaling by altering specific amino acid sequences, maintaining CXCL12-binding and signaling via CXCR4, thereby promoting tissue regeneration without inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If fully-reduced HMGB1 is used to promote tissue regeneration, then regenerative activity is enhanced, but proinflammatory signaling through TLR-2, TLR-4, and RAGE is induced
Solution Approach 1:
The patent extracts and removes the proinflammatory signaling capability from HMGB1 by substituting cysteine residues with serine, creating a variant that retains regenerative function while eliminating harmful inflammatory pathways. This selective extraction of the harmful component resolves the contradiction between regeneration and inflammation.
Solution Approach 2:
The patent changes the chemical parameter of HMGB1 by substituting cysteine residues with serine, altering the protein's redox state and receptor binding properties. This parameter change eliminates TLR-2, TLR-4, and RAGE signaling while preserving CXCL12-CXCR4-mediated regenerative activity.
2Object-generated harmful factors
If HMGB1 is modified to eliminate TLR-2 and RAGE signaling, then inflammatory responses are reduced, but regenerative activity may be compromised
Solution Approach 1:
The patent applies local quality modification by selectively substituting only the cysteine residues involved in proinflammatory receptor binding (TLR-2, TLR-4, RAGE) while preserving the structural and functional integrity of the CXCL12 binding site. This localized modification ensures anti-inflammatory effect without sacrificing regenerative capability.
Solution Approach 2:
The patent uses serine as an intermediary amino acid to replace cysteine residues. Serine maintains the protein structure and CXCL12 binding function while preventing interaction with TLR-2, TLR-4, and RAGE receptors, thus mediating between structural integrity and anti-inflammatory function.
3Productivity
If exogenous stem cells are administered to promote regeneration, then cell replacement is achieved, but inflammatory environment and scarring prevent successful engraftment
Solution Approach 1:
The patent converts the harmful inflammatory environment into a beneficial regenerative environment by using the modified HMGB1 variant to selectively activate CXCR4 on stem cells, promoting their migration and differentiation without triggering the harmful inflammatory cascade that would otherwise prevent engraftment.
Solution Approach 2:
The modified HMGB1 acts as an intermediary molecule that mediates between the extracellular environment and stem cells, providing regenerative signals through CXCR4 while blocking proinflammatory signaling pathways, thus creating a permissive environment for stem cell engraftment and tissue regeneration.
Data Source
AI summary
This invention provides polypeptides represented by the following formula:H2N-A-X-B-A-X-B-HOOCwhich are based on HMGB1 as well as compositions comprising, and treatment methods using, such polypeptide.